SKF-86002

Research use only, not for human use.

SKF-86002 is a potent inhibitor of p38 MAPK with IC50 of 0.5-1 uM, inhibits LPS-induced IL-1 and TNF-α production in human monocyte with IC50 of 1 uM.

SKF-86002 is a potent inhibitor of p38 MAPK with IC50 of 0.5-1 uM, inhibits LPS-induced IL-1 and TNF-α production in human monocyte with IC50 of 1 uM; inhibits prostaglandin H2 (PGH2) synthase activity (IC50=120 uM) as well as prostanoid production by rat basophilic leukemia (RBL-1) cells (IC50=70 uM); blocks superoxide anion production in response to FMLP and reduces adhesion and chemotaxis in response to PAF or FMLP in human neutrophils; also inhibits 5-lipoxygenase- and cyclooxygenase-mediated arachidonic acid metabolism in RBL-1 cells (IC50=10 and 100 uM respectively), shows anti-inflammatory in vivo.

Western Blot Analysis Cell Line:U937 cells Concentration:10 μM Incubation Time:72 hours Result:Significantly reduced CD23 levels on IL-4-treated U937 cells.

Animal Model:Lewis rats, with adjuvant-induced arthritis (AA) Dosage:10 mg/kg, 30 mg/kg, 90 mg/kg Administration:Oral administration, daily, for 22 days Result:Significantly decreased hindleg volumes after injection of adjuvant.

SKF86002

MAPK/ERK Signaling

p38 MAPK

p38MAPK

Inflammation/Immunology

——

72873-74-6

297.35

C16H12FN3S

>98% (HPLC)

10 mM in DMSO

FC1=CC=C(C2=C(C3=CC=NC=C3)N4C(SCC4)=N2)C=C1

Imidazo[2,1-b]thiazole, 6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)-

(-20℃)

With Ice Pack

≥ 2 years